ICAD

ICAD Inc

Add to Watchlist

Advanced Chart

0.000

-3.87(-100.000%)1D

Overview
Forecast
Valuation
Earnings

High

Open

VWAP

Vol

Mkt Cap

34.50M

Low

Amount

EV/EBITDA(TTM)

Total Shares

26.54M

86.28M

EV/OCF(TTM)

P/S(TTM)

5.24

iCAD, Inc. provides artificial intelligence-powered cancer detection. Its ProFound Breast Health Suite enables medical providers and professionals to accurately and reliably identify where cancer may be hiding. Its Cancer Detection segment solutions include advanced artificial intelligence and image analysis workflow solutions that enable healthcare professionals to serve patients by identifying pathologies and pinpointing the prevalent cancers earlier, a range of upgradeable computer-aided detection systems and workflow solutions for digital breast tomosynthesis, full-field digital mammography, magnetic resonance imaging and computed tomography. ProFound Suite offers 360-degree solutions for cancer detection, density assessment, and personalized risk evaluation, all based on a two-dimensional or three-dimensional mammogram’s collection of images. ProFound Density Assessment standardizes and simplifies breast density reporting and algorithmically examining.

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2025Q4

FY2025Q3

FY2025Q2

5.44M

+0.66%

-0.040

+33.33%

4.84M

+14.73%

-0.050

-28.57%

4.82M

-4.18%

-0.057

-19.04%

Estimates Revision

The market is revising Upward the revenue expectations for iCAD, Inc. (ICAD) for FY2025, with the revenue forecasts being adjusted by 4.19% over the past three months. During the same period, the stock price has changed by 4.31%.

Revenue Estimates for FY2025

Revise Upward

+4.19%

In Past 3 Month

EPS Estimates for FY2025

Revise Upward

+6.25%

In Past 3 Month

Stock Price

Go Up

+4.31%

In Past 3 Month

3 Analyst Rating

Wall Street analysts forecast ICAD stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ICAD is 3.25 USD with a low forecast of 3.00 USD and a high forecast of 3.50 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

0 Buy

3 Hold

0 Sell

Hold

Current: 0

Low

3.00

Averages

3.25

High

3.50

Current: 0

Low

3.00

Averages

3.25

High

3.50

Laidlaw & Co.

Yale Jen

Strong Buy

Hold

Downgrades

n/a

2025-04-17

Reason

Laidlaw & Co.

Yale Jen

Price Target

n/a

2025-04-17

Downgrades

Strong Buy

Hold

Reason

Laidlaw analyst Yale Jen downgraded iCAD (ICAD) to Hold from Buy without a price target after the company announced it will be acquired by DeepHealth, a subsidiary of traded RadNet (RNDT). Although the valuation of the acquisition is "only modest," it offers iCAD investors a more immediate investment exit under the current more turbulent macro investment environment, the analyst tells investors in a research note.

See All Ratings

Valuation Metrics

The current forward P/E ratio for ICAD Inc (ICAD.O) is -21.01, compared to its 5-year average forward P/E of -19.51. For a more detailed relative valuation and DCF analysis to assess ICAD Inc 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

-19.51

Current PE

-21.01

Overvalued PE

3.00

Undervalued PE

-42.03

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

30.07

Current EV/EBITDA

0.00

Overvalued EV/EBITDA

281.69

Undervalued EV/EBITDA

-221.54

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

Fair

5Y Average PS

4.24

Current PS

5.16

Overvalued PS

7.25

Undervalued PS

1.24

Financials

Annual

Quarterly

FY2025Q1

YoY :

-1.61%

4.87M

Total Revenue

FY2025Q1

YoY :

-21.65%

-1.13M

Operating Profit

FY2025Q1

YoY :

-31.83%

-833.00K

Net Income after Tax

FY2025Q1

YoY :

-40.00%

-0.03

EPS - Diluted

FY2025Q1

YoY :

-104.51%

58.00K

Free Cash Flow

FY2025Q1

YoY :

+3.73%

84.80

Gross Profit Margin - %

FY2025Q1

YoY :

-53.93%

-14.18

FCF Margin - %

FY2025Q1

YoY :

-30.73%

-17.09

Net Margin - %

Trading Trends

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

0-3

Months

0.0

USD

3-6

Months

0.0

USD

6-9

Months

0.0

USD

0-12

Months

0.0

USD

Bought

0-3

0.0

USD

Months

3-6

0.0

USD

Months

6-9

0.0

USD

Months

0-12

0.0

USD

Months

Hedge Fund

Hedge Funds are Neutral. There are no significant trading trends over the last quarter.

Sold

0-3

Months

0.0

Volume

3-6

Months

0.0

Volume

6-9

Months

0.0

Volume

0-12

Months

0.0

Volume

Bought

0-3

0.0

Volume

Months

3-6

0.0

Volume

Months

6-9

0.0

Volume

Months

0-12

0.0

Volume

Months

Congress Trading

Congress are Neutral. There are no significant trading trends over the last month.

Sold

0-3

Months

0.0

USD

3-6

Months

0.0

USD

6-9

Months

0.0

USD

0-12

Months

0.0

USD

Bought

0-3

0.0

USD

Months

3-6

0.0

USD

Months

6-9

0.0

USD

Months

0-12

0.0

USD

Months

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

0-3

Months

0.0

USD

3-6

Months

0.0

USD

6-9

Months

0.0

USD

0-12

Months

0.0

USD

Bought

0-3

0.0

USD

Months

3-6

0.0

USD

Months

6-9

0.0

USD

Months

0-12

0.0

USD

Months

ICAD News & Events

Events Timeline

2025-07-17 (ET)

2025-07-17

09:05:17

RadNet's DeepHealth complete acquisition of iCAD

2025-07-08 (ET)

2025-07-08

08:20:04

iCAD's proposed acquisition by RadNet recommended by ISS, Glass Lewis

2025-05-13 (ET)

2025-05-13

16:22:54

iCAD reports Q1 EPS (3c), consensus (6c)

News

7.0

06-15Globenewswire

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates LNSR, ATAI, ICAD on Behalf of Shareholders

7.0

06-15Globenewswire

HAPPY FATHER’S DAY and $HARHOLDER ALERT: The M&A Class Action Firm Continues to Investigate the Merger: SVT, SSBK, LNSR, iCAD

7.0

06-09Globenewswire

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates SVT, LNSR, ICAD, SSBK on Behalf of Shareholders

People Also Watch

Crown LNG Holdings Ltd

USD

-64.69%

PVL

Permianville Royalty Trust

Office Properties Income Trust

LakeShore Biopharma Co Ltd

Xilio Therapeutics Inc

FAQ

What is ICAD Inc (ICAD) stock price today?

The current price of ICAD is 0 USD — it has increased 3.62 % in the last trading day.

ICAD

Market Estimates

Valuation Metrics

Forward PE

Forward EV/EBITDA

Forward PS

Financials

Trading Trends

ICAD News & Events

Events Timeline

News

People Also Watch

FAQ

What is ICAD Inc (ICAD) stock price today?

What is ICAD Inc (ICAD)'s business?

What is the price predicton of ICAD Stock?

What is ICAD Inc (ICAD)'s revenue for the last quarter?

What is ICAD Inc (ICAD)'s earnings per share (EPS) for the last quarter?

What changes have occurred in the market's expectations for ICAD Inc (ICAD)'s fundamentals?

How many employees does ICAD Inc (ICAD). have?

What is ICAD Inc (ICAD) market cap?